BioXcel Therapeutics, Inc. financial data

Symbol
BTAI on Nasdaq
Location
New Haven, CT
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 122% % -49%
Quick Ratio 1.9% % -75%
Debt-to-equity -139% % 28%
Return On Equity 72% % -27%
Return On Assets -185% % -76%
Operating Margin -6738% % -100%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21,869,491 shares -49%
Common Stock, Shares, Outstanding 19,996,000 shares -53%
Entity Public Float $41,276,960 USD -69%
Common Stock, Value, Issued $73,000 USD 74%
Weighted Average Number of Shares Outstanding, Basic 14,196,000 shares 436%
Weighted Average Number of Shares Outstanding, Diluted 14,196,000 shares 436%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $752,000 USD -67%
Research and Development Expense $29,451,000 USD -15%
Costs and Expenses $51,424,000 USD -35%
Operating Income (Loss) $50,672,000 USD 34%
Net Income (Loss) Attributable to Parent $68,211,000 USD 3.9%
Earnings Per Share, Basic -7 USD/shares 94%
Earnings Per Share, Diluted -7 USD/shares 94%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $36,176,000 USD -10%
Inventory, Net $459,000 USD -70%
Other Assets, Current $934,000 USD -33%
Assets, Current $44,403,000 USD -7.1%
Property, Plant and Equipment, Net $249,000 USD -55%
Operating Lease, Right-of-Use Asset $140,000 USD -70%
Other Assets, Noncurrent $0 USD -100%
Assets $44,792,000 USD -8.4%
Accounts Payable, Current $16,276,000 USD 9.3%
Employee-related Liabilities, Current $35,000 USD -10%
Accrued Liabilities, Current $4,363,000 USD -57%
Liabilities, Current $37,804,000 USD 48%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $133,711,000 USD -0.6%
Retained Earnings (Accumulated Deficit) $707,549,000 USD -11%
Stockholders' Equity Attributable to Parent $88,919,000 USD -3.8%
Liabilities and Equity $44,792,000 USD -8.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $12,043,000 USD 32%
Net Cash Provided by (Used in) Financing Activities $13,202,000 USD -50%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 19,996,000 shares -53%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,159,000 USD -87%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $37,320,000 USD -7.6%
Deferred Tax Assets, Valuation Allowance $192,149,000 USD 11%
Operating Lease, Liability $161,000 USD -70%
Depreciation $303,000 USD -2.3%
Lessee, Operating Lease, Liability, to be Paid $163,000 USD -70%
Property, Plant and Equipment, Gross $1,977,000 USD 0%
Operating Lease, Liability, Current $161,000 USD -56%
Lessee, Operating Lease, Liability, to be Paid, Year Two $65,000 USD -83%
Lessee, Operating Lease, Liability, to be Paid, Year One $65,000 USD -83%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,000 USD -91%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $618,557,000 USD 12%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $600,000 USD 205%
Share-based Payment Arrangement, Expense $2,118,000 USD -79%
Interest Expense $13,554,000 USD 17%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%